Dataset from A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema

The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE.Participants will be treated with lanadelumab for 26 weeks.

本研究的主要目的为评估拉那芦单抗（lanadelumab）在中国遗传性血管性水肿（HAE）受试者中的安全性。受试者将接受拉那芦单抗治疗，疗程为26周。